Cencora, Inc. logo COR - Cencora, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 33
HOLD 12
SELL 1
STRONG
SELL 0
| PRICE TARGET: $357.75 DETAILS
HIGH: $400.00
LOW: $330.00
MEDIAN: $350.00
CONSENSUS: $357.75
UPSIDE: 5.69%

Stock News

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Passage Bio, Inc. (Nasdaq – PASG), American Oncology Network, Inc. (OTCQX – AONC), Utz Brands, Inc. (NYSE – UTZ), Finward Bancorp (Nasdaq – FNWD)

BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Oct 21, 2026 07:28 AM • globenewswire.com
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. “The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “AON serves as a trusted p.

Oct 21, 2026 03:30 AM • businesswire.com
Cencora (NYSE:COR) and Option Care Health (NASDAQ:OPCH) Financial Contrast

Cencora (NYSE:COR) and Option Care Health (NASDAQ:OPCH) Financial Contrast

Cencora (NYSE: COR - Get Free Report) and Option Care Health (NASDAQ: OPCH - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Earnings and Valuation This table compares Cencora and

Oct 17, 2026 12:01 AM • defenseworld.net
AI Disruption May Benefit Cencora More Than Hims & Hers

AI Disruption May Benefit Cencora More Than Hims & Hers

Cencora (COR) stands to benefit from AI-driven increases in prescription volumes as regulatory pilots expand automated prescribing. COR's operational leverage and AI-enabled efficiency improvements have driven adjusted operating income up 17% YoY, outpacing 4.9% sales growth. Trading at a forward GAAP P/E of 17.7x—about 25% below sector median—COR merits a 12.5% re-rating, targeting $365–$366 per share.

Oct 14, 2026 05:38 AM • seekingalpha.com
Hims & Hers Health (NYSE:HIMS) vs. Cencora (NYSE:COR) Head to Head Review

Hims & Hers Health (NYSE:HIMS) vs. Cencora (NYSE:COR) Head to Head Review

Cencora (NYSE: COR - Get Free Report) and Hims and Hers Health (NYSE: HIMS - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk. Valuation and Earnings This table compares Cencora

Oct 11, 2026 09:28 PM • defenseworld.net
Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2026 on Wednesday, November 4, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 4, 2026.Participating in the conference call will be:Robert P. Mauch, President & Chief Executive OfficerEva C. Boratto, Executive Vice President & Chie.

Oct 02, 2026 04:00 AM • businesswire.com
Cencora Elects Robert E. Sanchez to Its Board of Directors

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executive Chair of Ryder System, Inc., where he previously served as Chair and Chief Executive Officer until his retirement in March 2026. Prior to being appointed CEO in 2013, Mr. Sanchez spent two decades with Ryder serving in roles of increasing responsibility including President an.

Sep 25, 2026 04:00 AM • businesswire.com
Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Officer Bob Mauch said Cencora's growth is being supported by pharmaceutical innovation, demographic trends and the company's long-standing investments in specialty distribution and

Sep 21, 2026 02:03 AM • defenseworld.net

Price Targets